SEC Form 4 · accession 0001209191-18-056519
Odonate Therapeutics, Inc. · ODT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Kevin C Tang
Officer — Chief Executive Officer · Director · 10% Owner
TANG CAPITAL PARTNERS LP
10% Owner
TANG CAPITAL MANAGEMENT LLC
10% Owner
John G Lemkey
Officer — Chief Financial Officer
Period of report
Oct 26, 2018
Accepted (ET)
Oct 30, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001717452
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 26, 2018 | P | 235 | $15.85 | A | 12,702,338 | I | By LP |
| Common StockF2,F1 | Oct 29, 2018 | P | 10,000 | $14.9642 | A | 12,712,338 | I | By LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Tang and Mr. Lemkey both have a pecuniary interest in a portion of the shares beneficially held by TCP.
- F2The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $14.81 to $15.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth herein.